Study #2023-0124
A phase 1/2, open-label, multi-center study of ZN-c3 administered in combination with Encorafenib and Cetuximab in adults with metastatic Colorectal cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
ZN-c3, Encorafenib, Cetuximab
Description
The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Colorectal Cancer
Study phase:
Phase I
Physician name:
Christine Parseghian
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.